Replies to post #429956 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Wimike,

Apple currently has over 16 billion shares outstanding, while Tesla is just over a billion, I don't believe anyone can say they haven't achieved tremendous success. Certainly we'd be at substantially higher prices now if fewer shares existed, but I have no doubt that we can reach the Nasdaq again, or perhaps the NYSE once the trial information becomes public. Once that's been achieved, does it really matter if our market cap reaches double or triple digit billions with a couple billion shares outstanding, or if the shares were below one billion.

I believe that our market cap could reach double digit billions next year, perhaps in excess of 20 billion if a partnership occurs, which I believe the odds are roughly even for. Triple digit billions will probably require validation that the vaccine works in a few other cancers, but not necessarily full regulator approvals. Many approved products are utilized with full insurance coverage for off label uses where regulators never change the label, and the label changes aren't pursued. Some of the products used in my leukemia treatment certainly fell into that category.

I don't know how many patients have already received the vaccine off label, but I know some have been, apparently successfully. It's anecdotal evidence, once approved, off label use will grow, largely from wealthy patients willing to pay, but as anecdotal evidence build, insurance will be forced to pay if necessary. What's never clear until evidence increases is whether costs of the new technology increases, or lowers the overall cost of treatment. While adding say a quarter million to the cost of treatment may sound expensive, if it results in a patient being cured it may save the cost of years of treatment that could have been avoided by that quarter million, so that quarter million might result in a tremendous savings. If an insurance company sees where its overall cost may be lower, it won't fight the use of an off label product.

The last thing I'd like to see is a reverse split. Yes it would bring the share count down and could slightly quicken the time to upgrade to a major exchange, it has negative connotations that can be overcome, but why do it when everything can be achieved once people know what we have here. Frankly if the data wasn't good, it wouldn't matter what exchange we were on, we'd tank.

Gary